Elicio Therapeutics (ELTX) Other Non-Current Liabilities (2022 - 2026)

Elicio Therapeutics (ELTX) has reported Other Non-Current Liabilities for 5 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 70.79% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (down 70.79% YoY), and the FY2025 full-year result was $2.6 million, down 7.53% from the prior year.
• Other Non-Current Liabilities eased to $1.1 million in Q2 2026 per ELTX's latest filing, from $3.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $23.2 million in Q3 2024 and bottomed at $11000.0 in Q4 2023.
• Historically, Other Non-Current Liabilities has averaged $4.3 million across 5 years, with a median of $3.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities jumped 25609.09% in 2024, then slumped 83.28% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $81000.0 in 2022, then plunged by 86.42% to $11000.0 in 2023, then surged by 25609.09% to $2.8 million in 2024, then fell by 7.53% to $2.6 million in 2025, then tumbled by 57.32% to $1.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.1 million, $3.6 million, and $2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.